386 Shares in argenx SE (NASDAQ:ARGX) Acquired by Financial Advocates Investment Management

Financial Advocates Investment Management bought a new stake in shares of argenx SE (NASDAQ:ARGX) in the fourth quarter, HoldingsChannel reports. The institutional investor bought 386 shares of the company’s stock, valued at approximately $237,000.

A number of other hedge funds and other institutional investors have also added to or reduced their stakes in the business. Cromwell Holdings LLC grew its position in shares of argenx by 73.3% during the 3rd quarter. Cromwell Holdings LLC now owns 156 shares of the company’s stock valued at $85,000 after acquiring an additional 66 shares during the period. GAMMA Investing LLC raised its holdings in argenx by 47.5% in the 3rd quarter. GAMMA Investing LLC now owns 174 shares of the company’s stock worth $94,000 after purchasing an additional 56 shares during the period. Blue Trust Inc. lifted its position in argenx by 413.9% during the third quarter. Blue Trust Inc. now owns 370 shares of the company’s stock valued at $201,000 after purchasing an additional 298 shares in the last quarter. Keudell Morrison Wealth Management bought a new stake in argenx during the third quarter valued at about $207,000. Finally, SG Americas Securities LLC increased its position in argenx by 6.2% in the fourth quarter. SG Americas Securities LLC now owns 358 shares of the company’s stock worth $220,000 after buying an additional 21 shares in the last quarter. 60.32% of the stock is owned by hedge funds and other institutional investors.

argenx Stock Down 1.7 %

argenx stock opened at $646.64 on Monday. argenx SE has a twelve month low of $349.86 and a twelve month high of $678.21. The company’s 50-day moving average price is $637.11 and its 200-day moving average price is $577.73. The company has a market cap of $39.29 billion, a PE ratio of -734.82 and a beta of 0.58.

Analyst Ratings Changes

A number of research firms have recently weighed in on ARGX. Oppenheimer reaffirmed an “outperform” rating and set a $675.00 price objective (up from $646.00) on shares of argenx in a research report on Thursday, November 21st. Truist Financial reiterated a “buy” rating and issued a $700.00 price target (up from $660.00) on shares of argenx in a research report on Tuesday, January 14th. Deutsche Bank Aktiengesellschaft downgraded shares of argenx from a “hold” rating to a “sell” rating in a research report on Friday, January 17th. Scotiabank upgraded shares of argenx from a “sector perform” rating to a “sector outperform” rating and lifted their target price for the company from $439.00 to $715.00 in a research note on Tuesday, November 5th. Finally, Citigroup increased their price target on argenx from $512.00 to $635.00 and gave the stock a “buy” rating in a research note on Thursday, October 17th. One analyst has rated the stock with a sell rating, two have assigned a hold rating, eighteen have given a buy rating and one has given a strong buy rating to the company’s stock. Based on data from MarketBeat.com, the company has a consensus rating of “Moderate Buy” and an average price target of $658.39.

argenx Profile

argenx SE, a biotechnology company, engages in the developing of various therapies for the treatment of autoimmune diseases in the United States, Japan, Europe, Middle East, Africa, and China. Its lead product candidate is efgartigimod for the treatment of patients with myasthenia gravis, immune thrombocytopenia, pemphigus vulgaris, generalized myasthenia gravis, chronic inflammatory demyelinating polyneuropathy, thyroid eye disease, bullous pemphigoid, myositis, primary sjögren’s syndrome, post-covid postural orthostatic tachycardia syndrome, membranous nephropathy, lupus nephropathy, anca-associated vasculitis, and antibody mediated rejection; ENHANZE SC; Empasiprubart for multifocal motor neuropath, delayed graft function, and dermatomyositis; and ARGX-119 for congenital myasthenic syndrome and amyotrophic lateral sclerosis.